Business Segments · Research and development expense
Business Segments — Research and development expense
Guardant Health Business Segments — Research and development expense decreased by 10.9% to $76.59M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.3%, from $74.90M to $76.59M. Over 3 years (FY 2022 to FY 2025), Business Segments — Research and development expense shows relatively stable performance with a -3.3% CAGR.
Analysis
StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026May 7, 2026
How to read this metric
Higher spending reflects a commitment to innovation and future growth, though excessive spending without corresponding revenue growth may signal inefficient R&D processes.
Detailed definition
These are the costs incurred to discover, develop, and improve the company's diagnostic technologies and clinical test p...
Peer comparison
Standard R&D expense reporting for biotechnology and medical device companies.
Metric ID:
gh_segment_reportable_segment_research_and_development_expenseHistorical Data
17 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $85.41M | $85.41M | $85.41M | $85.41M | $82.46M | $82.46M | $82.46M | $82.46M | $73.36M | $72.99M | $68.37M | $81.15M | $74.90M | $72.55M | $75.79M | $85.94M | $76.59M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -3.5% | +0.0% | +0.0% | +0.0% | -11.0% | -0.5% | -6.3% | +18.7% | -7.7% | -3.1% | +4.5% | +13.4% | -10.9% |
| YoY Change | — | — | — | — | -3.5% | -3.5% | -3.5% | -3.5% | -11.0% | -11.5% | -17.1% | -1.6% | +2.1% | -0.6% | +10.9% | +5.9% | +2.3% |
Range$68.37M – $85.94M
CAGR-2.7%
Avg YoY Growth-2.7%
Median YoY Growth-3.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Guardant Health's business segments — research and development expense?
- Guardant Health (GH) reported business segments — research and development expense of $76.59M in Q1 2026.
- How has Guardant Health's business segments — research and development expense changed year-over-year?
- Guardant Health's business segments — research and development expense increased by 2.3% year-over-year, from $74.90M to $76.59M.
- What is the long-term trend for Guardant Health's business segments — research and development expense?
- Over 3 years (2022 to 2025), Guardant Health's business segments — research and development expense has grown at a -3.3% compound annual growth rate (CAGR), from $341.65M to $309.18M.
- What does business segments — research and development expense mean?
- The amount spent on developing new products and improving existing technologies.